Background. Septic arthritis is associated with residual dysfunction in 10 to 25% of affected children. Concentrations of cytokines detected in synovial fluid of children with bacterial arthritis correlate with the severity of inflammation. Treatment with dexamethasone decreased cartilage degradation in experimental Haemophilus influenzae b and Staphylococcus aureus arthritis.
INTRODUCTION
Pyogenic arthritis is associated with estimated residual dysfunction in 10 to 25% of affected children; it may not become apparent for months or years after and includes abnormalities of bone growth, limitation of joint mobility, unstable articulation and chronic dislocation of the joint. 1, 2 A number of possible mechanisms of articular damage associated with inflammation have been described. High concentrations of cytokines have been detected in synovial fluid of children with bacterial arthritis, and the concentrations of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1-beta (IL-1-beta) have been shown to correlate significantly with the severity of inflammation. 3 Treatment with dexamethasone decreased cartilage degradation in experimental rabbit Haemophilus influenzae b arthritis. 4 These authors found a significant reduction of synovial fluid neutrophil concentration, IL-1-beta, TNF-alpha and stromelysin in dexamethasone-treated rabbits. They suggested that IL-1 mediated cartilage degradation by regulation of metalloproteinases such as stromelysin, during acute experimental arthritis.
In the murine model of hematogenously acquired Staphylococcus aureus arthritis, iv dexamethasone with or without antibiotics decreased the prevalence and severity of arthritis. Immunohistochemical analysis revealed a decrease in T cells and macrophages in the synovium of mice that received the combined therapy; serum levels of interferon-gamma were decreased 15-fold in the steroid and antibiotic-treated animals as well as were serum NO 3 Ϫ concentrations. 5 On the basis of this information, we undertook a double blind, placebo-controlled trial of dexamethasone administered as adjuvant therapy to patients with hematogenous bacterial arthritis. Our primary endpoint was to decrease the number of patients with sequelae or dysfunction of the affected joint at the end of therapy and at 6 and 12 months of follow-up. Secondary end-points were to assess the fall of serum C-reactive protein (CRP) and the speed of clinical recovery during the acute phase among the two sets of patients.
SUBJECTS AND METHODS
Inclusion criteria. This double blind, placebocontrolled study was conducted at Hospital Nacional de Niñ os, San José, Costa Rica. Children Ͼ3 months old and younger than 13 years of age whose parents or legal guardians provided written informed consent were eligible for the study. Approval of the study protocol was obtained from the review board of the institution. Documented septic arthritis was considered when there were (1) bacterial growth and purulence of the synovial fluid (purulence was defined as the presence of Ն5000 white blood cells/mm 3 , Ͼ60% of segmented forms, lactate dehydrogenase (LDH) Ͼ500 IU, glucose Ͻ30 mg/dl) or (2) bacteria isolated from blood and presence of a purulent synovial fluid with or without bacteria seen in the Gram-stained smear.
Exclusion criteria. Patients were excluded from enrollment or from follow-up evaluation if they had a previous history of septic arthritis in the same or the contralateral joint; if arthritis was secondary to a puncture wound; if there was a known history of autoimmune disease; if patients had received steroids in the previous 2 months (except for asthma); if they had congenital or acquired osteoarticular anomalies, a history of a foreign body in the affected joint or Gramnegative coliform bacilli isolated from blood, cerebrospinal fluid, articular fluid or another significant body fluid; if they had an underlying disease that would preclude the long term (12 months) evaluation; or if they had received Ͼ48 h of treatment with an orally or parenterally administered antibiotic.
Diagnostic procedures. Arthrocentesis and ultrasound were performed within the first 12 h of admission. Whenever bone involvement was suspected (age Ͻ36 months or strong clinical suspicion), a bone scan was performed.
Prognostic score. Patients were given a prognostic score that evaluated: concurrent bone involvement, 2 points; hip or shoulder involvement, 3 points; age Ͻ6 months, 2 points; Ͼ4 days of symptoms before enrollment, 2 points; disease caused by S. aureus, 2 points. 1, 2, 6 Procedures. All patients underwent a diagnostic arthrocentesis by one of the orthopedic surgeons; it was repeated whenever there was reaccumulation of fluid. Arthrotomy was performed by the Orthopedics Department if there was hip involvement reaccumulation of pus after three consecutive arthrocenteses of the knee joint.
Antibiotic therapy. The study was initiated 2 months before the conjugate H. influenzae type b (Hib) vaccine became available for the whole pediatric population of the country. Therefore empiric therapy for children Ͻ5 years old consisted of ampicillin plus oxacillin; children Ͼ5 years were started on oxacillin. Pathogen-specific therapy consisted of oxacillin (50 mg/kg/dose every 6 h iv) for methicillin-susceptible strains and vancomycin (10 mg/kg/dose every 6 h) for those that were resistant. Patients with ampicillinsusceptible Hib disease were treated with ampicillin (50 mg/kg/dose every 6 h iv), and those who were resistant received cefotaxime (50 mg/kg/dose every 8 h iv). Patients with penicillin-susceptible pneumococcus continued to receive oxacillin until the end of iv therapy. Patients received 7 days of iv therapy followed by 7 days or more of ambulatory oral therapy. Cephalexin 100 mg/kg/day administered every 8 h was given to patients with methicillin-susceptible staphylococci. Patients with ampicillin-susceptible Hib were discharged receiving amoxicillin (100 mg/kg/day administered every 8 h), and those with resistant strains were discharged to receive trimethoprim-sulfamethoxazole (40 mg/kg/day administered every 12 h). The change to oral therapy was made when there was evidence of clinical improvement, absence of reaccumulation of joint fluid and a normal CRP.
Adjuvant therapy. After enrollment patients were selected from a list of computer-generated random numbers kept by the Pharmacist (GA) to receive in a 1:1 randomization: dexamethasone [Decadron (Vnr.05798, 4 mg/dl; Merck Sharp and Dohme)] 0.2 mg/kg/dose iv every 8 h for 12 consecutive doses; or saline at an equivalent volume of that of the corresponding dexamethasone, given iv at the same intervals and number of doses. The first dose of dexamethasone or placebo was administered 15 to 20 min before the first dose of parenteral antibiotics. Treatment was allocated by opening of sequential, blinded envelopes containing drug assignments.
Clinical and laboratory assessment. Patients were examined daily by CMO or IH and twice a week by one of the orthopedic surgeons. The recorded information consisted of presence of spontaneous pain, pain induced by motion, pain to touch, edema, warmth of the affected joint, circumference when applicable (knee, ankle, wrist, elbow), range of motion and degree of claudication (depending on the age of the patient).
A serum sample for determination of CRP was obtained daily until normal. A stool guaiac was performed on admission and every two days while on dexamethasone.
Measurement of joint damage. Angles of joint movement were measured by one of the orthopedic surgeons with a goniometer and compared with those of the contralateral healthy joint. For the knee joint angles of flexion and extension were measured; for the shoulder elevation, extension, internal and external rotation; for the elbow flexion and extension; for the hip extension, flexion, abduction, adduction, internal and external rotation; for the ankle flexion or dorsiflexion and extension or plantar flexion; for the wrist flexion, extension, internal and external rotation. Normal angles of joint movement according to age and sex were taken from the guidelines of the American Academy of Orthopedic Surgeons. 7 The degree of impairment of joint movement in young children was determined after the normal ranges of motion of the different joints according to age, described in the guidelines of the American Academy of Orthopedic Surgeons, 7 and compared with the contralateral healthy joint.
Follow-up. Patients were followed clinically and radiologically at the end of treatment and at 6 and 12 months after discharge for the presence of anatomical or functional abnormalities of the affected joint following the criteria mentioned above.
Histopathologic examination. A small sample of synovial tissue and cartilage was obtained from patients who underwent arthrotomy. Histopathologic examination was performed after routine fixation and paraffin embedding.
Statistical analysis. The planned sample size of the study was 100 fully evaluable patients to detect a 20% difference in outcome using an ␣ of 0.05 and a ␤ of 0.2. The normal approximation to the binomial distribution was used to calculate 95% confidence intervals of the difference between the success rates. Fisher's exact test was used for hypothesis testing of no difference between the success rates.
RESULTS

Enrollment.
The study was conducted from January 2, 1998 to May 2000. Overall 123 children who were asked to participate were enrolled in the study; 61 received dexamethasone and 62 received placebo. Of the randomized patients 100 were fully evaluable (50 and 50 patients, respectively), and the remaining 23 children were unevaluable for various reasons (Table  1) .
Clinical and laboratory characteristics of the two treatment groups of patients were comparable. Demographic characteristics, mean duration of symptoms, prognostic score, affected joint, concurrent bone involvement, synovial fluid inflammatory indexes and distribution of pathogens were similar for the two treatment groups (Table 2) .
Microbiology. S. aureus was most frequently identified from evaluable patients accounting for 67% of the isolates (including isolation from joint fluid and/or blood) followed by H. influenzae type b with 13% and Streptococcus pneumoniae with 9%. Less commonly encountered pathogens were Streptococcus pyogenes and coagulase-negative staphylococci. All S. aureus organisms were susceptible to oxacillin. All pneumococci and coagulase-negative staphylococci were susceptible to penicillin and oxacillin, respectively. Coagulase-negative staphylococci were considered pathogenic when isolated concomitantly from blood and joint fluid. All H. influenzae organisms were susceptible to ampicillin, trimethoprim-sulfamethoxazole and cefotaxime. Twenty-four patients in whom a pathogen failed to grow from synovial fluid had microorganisms in the Gram-stained smear, and/or a pathogen was recovered from blood. The microbiology is depicted in Table 3 . We were able to isolate a pathogen from 81% of the initial sample size and from 100% of those who were considered evaluable.
Outcome. Clinical outcomes of the fully evaluable patients at the end of treatment and at 6 and 12 months follow-up evaluations are shown in Table 4 . At the end of treatment 2 dexamethasone patients had residual dysfunction: one with ankle and tibial involvement had a Ͻ30-degree dorsiflexion and a Ͻ40-degree plantar flexion; the second, with hip involvement, had a Ͻ27-degree extension, Ͻ130-degree flexion, Ͻ 45-degree abduction, Ͻ27-degree adduction and Ͻ40-degree internal and external rotation and was limping. Sixteen placebo patients had dysfunction: 9 had hip involvement with impaired angles of movement as described above, 6 were limping and 5 had persistent pain; 6 had knee arthritis with Ͻ90 degree flexion, and 3 of them had persistent pain; 1 had ankle involvement with impaired angles of movement as described above plus edema, limping and persistent pain. At 6 months of follow-up, 1 dexamethasone patient had hip involvement with impaired angles of movement, limping and shortening (2 cm) of the affected extremity. Nineteen placebo patients had dysfunction: 12 had hip involvement with impaired angles of movement (of them 6 were limping and 5 had shortening of the extremity); 6 had knee involvement with impaired angles of movement (of them 3 were limping and had chronic pain); 1 had ankle involvement with impaired angles of movement, limping, pain, edema and sclerosis of the astragalus on radiographic films. At 12 months of follow-up, 1 dexamethasone patient had hip involvement with the same features as those described at 6 months. Thirteen placebo patients had dysfunction: 12 had hip involvement with the same features as those described at 6 months; 1 had ankle involvement with limping and pain, and the radiographic films were normal. Dexamethasone and placebo patients had a normal CRP at 2.04 Ϯ 1.25 and at 4.68 Ϯ 6.23 days of therapy, respectively; P ϭ 0.01. Resolution of symptoms (absence of fever, absence of spontaneous pain or pain to passive or active movement, absence of warmth and edema, normal range of movement of the joint) took 2.34 Ϯ 5.06 and 7.81 Ϯ 2.04 days, respectively; P ϭ 0.001. Duration of intravenous/oral administration of antibiotics was 7.2 Ϯ 1.2/7.23 Ϯ 2.51 days for dexamethasone-treated patients and 10 Ϯ 5.6/9 Ϯ 2.62 days for those receiving placebo; P Ͻ 0.05. The number of arthrocenteses performed in dexamethasone and placebo patients (mean Ϯ SD; numbers in parentheses, range) was 1.14 Ϯ 1.6 (1 to 3) and 1.2 Ϯ 1.3 (1 to 3), respectively; arthrotomy was performed in 50% (25 of 50; 24 hips, 1 knee) and 50% (25 of 50; 23 hips, 2 knees) of the dexamethasone and placebo patients. In 6 each of dexamethasone and placebo patients, there was bone involvement documented by bone scan.
Histopathologic findings. Histopathologic analysis of synovial tissue and cartilage biopsy from 25 and 25 of dexamethasone and placebo patients showed findings of acute synovitis with variable degrees of cartilage destruction. Degree of cartilage destruction was similar in the two groups of patients.
DISCUSSION
Study results showed that early dexamethasone therapy speeds time of recovery and reduces residual dysfunction of patients with bacterial arthritis at the end of treatment, at 6 months and at 12 months. The 26% incidence of residual dysfunction in the control patients at 12 months of follow-up was similar to the 23% found by other authors.
1, 2
One weakness of this study was not measuring concentrations of TNF-alpha, IL-1-beta, chondroitin sulfate, stromelysin and other metalloproteinases in the joint fluid of the study patients. Measurement of these products has been shown to be a useful marker of cartilage metabolism and has been used to define pathogenetic processes in joint diseases including bacterial arthritis. 4, 8 -10 Chondroitin sulfate in synovial fluid correlates directly with the catabolic events that follow Hib infection.
11
Dexamethasone reduces synovial fluid inflammation mediators and decreases the severity of experimental Hib and S. aureus arthritis. 4, 5 Sakiniene et al. 5 demonstrated in the murine model of S. aureus arthritis that dexamethasone decreased histopathologically verified synovitis and the extent of cartilage and bone destruction by the suppression of T cell response and the reduction of the expression of adhesion molecules of T cells. They also showed that parallel to the decreased interferon-delta production there was a reduction in the number of phagocytic cells (Mac-1-positive) in the synovium of dexamethasone-treated animals. Destruction of articular cartilage is the crucial determinant of joint injury and dysfunction from inflammatory arthritides. Histopathologic analysis of cartilage obtained from 50 patients who underwent arthrotomy showed variable degrees of destruction. One could argue that arthrotomy and cartilage biopsy by themselves might have accounted for residual dysfunction; however, a similar number of patients underwent arthrotomy in the two therapeutic groups Patients with residual dysfunction at 12 months of follow-up had arthritis caused by S. aureus (dexamethasone 1, placebo 11); Hib (dexamethasone 0, placebo 2), suggesting that arthritis by S. aureus is more likely to cause permanent articular damage. With the sample size of this study, it was not possible to determine whether the beneficial effects of dexamethasone on the course and outcome of bacterial arthritis are pathogendependent or not. The small number of cases attributable to Streptococcus pneumoniae (9) , Streptococcus pyogenes (6) and coagulase-negative staphylococci (5) makes it difficult to draw any conclusions as to the effect of dexamethasone on the evolution and outcome of arthritis caused by these pathogens. We were able to isolate a pathogen from 81% of the initial sample size and from all evaluable patients; this might be because we did not enroll patients who had received antibiotics for Ն48 h.
Studies on the histopathologic progression of experimental S. aureus arthritis have shown that as early as 48 h after inoculation there is cartilage and subchondral destruction in 20% of the sample size. 12 The duration (mean Ϯ SD) of symptoms of our study patients was 2.1 Ϯ 2.2 days, which may have accounted for the 26% residual dysfunction observed in the control patients at 12 months of follow-up.
Measurement of serum CRP was a useful diagnostic and prognostic index to assess the response to therapy, as has been shown by other investigators. 13, 14 In dexamethasone-treated patients serum CRP values were reduced significantly faster than those of control patients; they experienced a favorable clinical response significantly faster than controls did and thus were switched to oral therapy at an earlier time. The quicker drop of serum CRP in the dexamethasone-treated patients could be explained by the fact that interleukin-6, the cytokine largely responsible for induction of CRP production acts synergistically with IL-1-beta and TNF-alpha and -delta, which in turn are modulated by dexamethasone. Because we did not measure cytokines in synovial fluid or serum of our patients, this is only a supposition.
In summary a short course of dexamethasone reduced residual joint dysfunction and shortened significantly the duration of symptoms in children with bacterial arthritis. These results suggest that that a 4-day course of dexamethasone given early in the evolution of septic arthritis offers short and long term benefits for children affected by this uncommon but incapacitating disease. 
